Lack of rapid revascularization and inflammatory attacks at the site of transplantation
contribute to impaired islet engraftment and suboptimal metabolic control after clinical islet …

Maintaining long-term euglycemia after intraportal islet transplantation is hampered by the
considerable islet loss in the peri-transplant period attributed to inflammation, ischemia and …

Pancreatic islet transplantation still represents a promising therapeutic strategy for curative
treatment of type 1 diabetes mellitus. However, a limited number of organ donors and …

Islet transplantation is a promising treatment for type 1 diabetes (T1D), yet the low donor
pool, poor islet engraftment, and life-long immunosuppression prevent it from becoming the …

We have developed a chamber model of islet engraftment that optimizes islet survival by
rapidly restoring islet-extracellular matrix relationships and vascularization. Our aim was to …

Islet transplantation is superior to extrinsic insulin supplementation in the treating severe
Type 1 diabetes. However, its efficiency and longevity are limited by substantial islet loss …

Intrahepatic islet transplantation is a promising β-cell replacement strategy for the treatment
of type 1 diabetes. Instant blood-mediated inflammatory reactions, acute inflammatory storm …

Pancreatic islet transplantation has been considered for many years a promising therapy for
beta-cell replacement in patients with type-1 diabetes despite that long-term clinical results …

Islet transplantation is a promising treatment for Type 1 diabetes; however limitations of the
intra-portal site and poor revascularization of islets must be overcome. We hypothesize that …

Pancreatic islet transplantation is an emerging therapy for type 1 diabetes. To survive and
function, transplanted islets must revascularize because islet isolation severs arterial and …